Open for bids Tender Germany ICB TOT Ref. 151593611

Conclusion not Excluding Drug Discount Agreement. Tender - 151593611

Tender notice from Germany, published on 28 Oct 2026.

Executive Summary

Title/Summary: This tender, issued by AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen, pertains to the establishment of non-exclusive discount agreements for the drug Infliximab for subcutaneous injection, under an Open-House model. The tender reference number is 159/2026-OH, with submissions due by June 30, 2028.

Scope Of Work: The scope involves entering into non-exclusive discount agreements for the drug Infliximab, as specified in § 130a Abs. 8 SGB V. The agreements will be available to all interested pharmaceutical companies during the participation period, contingent upon meeting the participation requirements. The volume of purchases is uncertain, dependent on various factors such as demand and physician prescribing behavior. Interested parties must download the participation documents from the German Procurement Portal (DTVP), following access approval. Communication will be conducted electronically, and confidentiality regarding the agreement terms is mandatory.

Qualification Criterion: Bidders must be pharmaceutical companies capable of meeting the participation criteria outlined in the project documents available on the DTVP. They need to submit an application for access to the project room to obtain the necessary participation documents. Confidentiality regarding the agreement terms is required, and any disclosure to third parties must be approved in writing by the issuer. All documents must be destroyed if the company decides not to participate.

Key facts

Summary
Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Infliximab for Subcutaneous Injection (Atc Code According to Who: L04ab02)
TOT Ref. No.
151593611
Document Ref. No.
Login to see
Country
Germany
Notice type
Tender
Competition
ICB
Publication date
28 Oct 2026
Bid deadline
30 Jun 2028
EMD
Refer Document
Tender value
Refer Document
Purchaser ownership
Public
Procurement Type
Goods
Financier
Self Financed

CPV classification

Purchaser details

Purchaser contact is for registered users

Login to see details

Tender details

Tender details are for registered users

Login to see details

Documents

Tender Notice
Login to view

Similar tenders

Germany Public Procurement Intelligence

Frequently asked questions

The last date to submit a bid for Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Infliximab for Subcutaneous Injection (Atc Code According to Who: L04ab02) is 30 Jun 2028. Submit before this date to be considered.

This tender has been issued by AOK PLUS - THE HEALTH INSURANCE FUND FOR SAXONY AND THURINGIA in Germany.

The tender value is not disclosed; please refer to the tender document. EMD / bid security details are provided in the tender document.

This tender is Self Financed

This is a Goods procurement tender issued as a public sector opportunity in Germany.

The tender is classified under the following CPV code(s): 33600000 - Pharmaceutical products.

The tender notice and related documents are listed in the Documents section above. Select a document to view or download it. Please log in or register to access the documents. If you cannot find additional documents in the Documents section, please log in to your account and Send Document Request from your account section.

The TendersOnTime reference is 151593611. The purchaser document reference is available after login.

See the Similar Tenders section on this page or browse other tenders from Germany.

This tender falls under Materials and Products, Technology and Equipment in Germany. Suppliers in these sectors can track similar Germany tenders using CPV-based alerts.